Drug Type Small molecule drug |
Synonyms |
Target |
Action agonists |
Mechanism κ opioid receptor agonists(Kappa opioid receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC23H28O8 |
InChIKeyOBSYBRPAKCASQB-AGQYDFLVSA-N |
CAS Registry83729-01-5 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Depressive Disorder, Treatment-Resistant | IND Application | United States | 28 Mar 2022 | |
Vasospasm, Intracranial | IND Application | - | - | |
Vasospasm, Intracranial | IND Application | - | - | |
Depressive Disorder | Preclinical | Canada | 19 May 2022 |
Phase 1/2 | 13 | kvpyzfqdvk(txzapoapbl) = urqlfrtxzs vhvykuyjaq (ylzaigonja, izipdxehte - wcazoobpbk) View more | - | 04 Mar 2021 | |||
Not Applicable | - | - | igguxviaaj(gbtpmcwstd) = SA decreased the MOR Bmax and increased the Kd in a dose-dependent manner that was not consistent with simple competitive inhibition ekcvcfbaxp (kkguqvtjce ) View more | - | 18 Oct 2006 | ||
Not Applicable | - | olgxyhbjxi(yggzttoyms) = vybvritwcf tzlqrkvadi (ndqatnjcng ) | - | 12 Nov 2005 |